BPC-157 & TB-500 & GHK-Cu (Triple Healing Stack) vs Cagrilintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157 & TB-500 & GHK-Cu (Triple Healing Stack)
The complete healing triad combining the Wolverine Stack with GHK-Cu (copper peptide) for comprehensive tissue repair. This blend addresses healing at multiple levels: cellular repair, collagen synthesis, and tissue regeneration.
Full details →Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 & TB-500 & GHK-Cu (Triple Healing Stack) | Cagrilintide |
|---|---|---|
| Mechanism | BPC-157 promotes angiogenesis and growth factor expression. TB-500 enhances cell migration and reduces inflammation. GHK-Cu activates genes involved in tissue remodeling, stimulates collagen and elastin production, and provides antioxidant protection. Together they support healing from multiple angles. | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. |
| Typical Dosage | Typical protocol: BPC-157 250-500mcg daily, TB-500 2-2.5mg twice weekly, GHK-Cu 1-2mg daily or applied topically for skin applications. | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. |
| Administration | BPC-157 and TB-500 via subcutaneous injection. GHK-Cu can be injected subcutaneously or used topically depending on the target area. Systemic and local administration may be combined. | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. |
| Side Effects | Generally well-tolerated. Possible injection site irritation, mild fatigue, or temporary skin discoloration with GHK-Cu. | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. |
| Best For |